Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Payables (2020 - 2025)

Historic Payables for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $698000.0.

  • Barinthus Biotherapeutics' Payables fell 7730.82% to $698000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $698000.0, marking a year-over-year decrease of 7730.82%. This contributed to the annual value of $2.5 million for FY2024, which is 5452.84% up from last year.
  • Latest data reveals that Barinthus Biotherapeutics reported Payables of $698000.0 as of Q3 2025, which was down 7730.82% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Barinthus Biotherapeutics' Payables registered a high of $5.1 million during Q3 2023, and its lowest value of $698000.0 during Q3 2025.
  • In the last 5 years, Barinthus Biotherapeutics' Payables had a median value of $2.5 million in 2024 and averaged $2.9 million.
  • Its Payables has fluctuated over the past 5 years, first skyrocketed by 11339.69% in 2023, then plummeted by 7730.82% in 2025.
  • Quarter analysis of 5 years shows Barinthus Biotherapeutics' Payables stood at $2.4 million in 2021, then skyrocketed by 54.94% to $3.7 million in 2022, then tumbled by 57.28% to $1.6 million in 2023, then surged by 54.53% to $2.5 million in 2024, then crashed by 71.79% to $698000.0 in 2025.
  • Its last three reported values are $698000.0 in Q3 2025, $1.8 million for Q2 2025, and $1.4 million during Q1 2025.